Ministry of Investment and Downstreaming/Investment Coordinating Board (BKPM) announced that Japanese biopharmaceutical company Takeda will invest up to US$30 million, or around Rp539 billion, in developing a plasma-derived drug product ecosystem in Indonesia.
This investment is the initial stage over two years to build a plasma bank network as a foundation for the development of the national plasma industry.
Minister of Investment and Downstreaming/Head of the Investment Coordinating Board (BKPM) Rosan Roeslani said that Takeda's investment reflects the growing confidence of global investors in Indonesia's investment prospects, particularly in the high-tech healthcare industry sector.
"This investment is a strategic investment that not only provides additional capital, but also opens up opportunities for technology transfer, human resource development, and the creation of high-skilled jobs. The government continues to encourage investments that provide added value and strengthen national industrial capacity so that Indonesia can become a center for manufacturing and health innovation in the region," he said.
According to him, this partnership is also in line with the economic transformation agenda through downstreaming in various strategic sectors, including health, to increase the competitiveness of the national industry and strengthen Indonesia's position in the global supply chain.
He stated that Japan itself is one of Indonesia's strategic investment partners. According to his records, in the first quarter of 2026, Japan ranked fifth among Indonesia's top investors, with investments reaching US$1 billion.
Meanwhile, Japan's total realized output from 2021 to the first quarter of 2026 reached US$18.1 billion, with an average growth rate of 13.2 percent, employing 299,460 people.
